lividomycin
Also Known As:
mannosyldeoxyparomomycin
Networked: 28
relevant articles (1 outcomes,
3 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Infections
|
2. | Pulmonary Tuberculosis
|
3. | Respiratory Tract Infections (Respiratory Tract Infection)
|
4. | Urinary Tract Infections (Urinary Tract Infection)
|
5. | Pneumonia (Pneumonitis)
04/01/1975
- " 1. A total of 13 patients with the following infectious diseases was treated with 1 g/day of lividomycin for 3 to 11 days (average 6.7 days): Acute pneumonia 3 cases, bronchiectasis 3 cases, acute bronchitis 5 cases, suppurative diseases of the lung 1 case, and pyothorax 1 case. " 04/01/1975
- " Therapeutic effects of lividomycin (LVDM) were studied in 33 patients with respiratory infections including pneumonia, lung abscess, chronic bronchitis, etc. LVDM was intramuscularly administered at the dose of 1 or 2 g per day for consecutive 4 to 25 days. " 04/01/1975
- " Therapeutic effect of lividomycin was observed in patients with infections of the respiratory tract (infections in association with bronchiectasis, mixed infections of cavities after negative conversion of tubercle bacilli, pneumonia, and so forth). "
|
|
Related Drugs and Biologics
Related Therapies and Procedures